SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Nuvo Research Inc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark Bartlett who wrote (3233)2/1/2000 9:07:00 PM
From: Montana Wildhack  Read Replies (1) of 14101
 
Mark,

That was a good article.

I can't imagine a revenue model for WF10.

What patients would qualify? It was mentioned
earlier that qualifying for the Phase III meant:

CD4+ count (less than 50 cells/mm3).
Blood iron level (hemoglobin >10.0 g/dL [men], and >9.0g/dL [women]).
White blood cell count (neutrophils > 750 cells/mm3).
Platelet levels (<75,000 cells/mm3).
Kidney function (creatinine < two times upper laboratory limit).

Would these conditions be required under normal
circumstances or is that just a condition of entering
the phase III study? This point was touched on just
a little while ago.

I've heard us say that this can be used in conjunction
with numerous cocktails and undertand why that would
be so - but how do I assess the number of people this
potentially applies to?

I'd like to move forward on this but need medical
opinions as to what patient conditions must exist
for WF10 to be viable.

Help!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News